Collectively, these facts indicate that the higher amount of IFN-I present in the therapy-applied Oasl1−/− lungs would stimulate both innate and adaptive immune cells and provide a higher number and better functioning of cytotoxic effector cells to the therapy-applied Oasl1−/− lungs, leading to improved tumor resistance and better survival of the treated Oasl1−/− mice. This evidence concerns the gene OASL and neoplasm.